Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
Verano to Report Third Quarter 2025 Financial Results on October 29, 2025
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA:…
